Appendix 3: Subgroup analysis for incidence rates of nonserious adverse events among people receiving medical cannabinoids and controls in randomized controlled trials

Group and subgroup	No. of trials	Pooled rate ratio (95% CI)	Heterogeneity		
			χ^2	*p* value	I^2, %
All studies	23	1.86 (1.57–2.21)	187.42	< 0.001	86.7
Oromucosal Δ-9-tetrahydrocannabinol-cannabidiol v. control	8	1.88 (1.48–2.39)	13.61	0.06	48.6
Duration of exposure					
> 2 wk	5	2.10 (1.76–2.49)	1.93	0.75	0
≤ 2 wk	3	1.38 (0.61–3.11)	7.64	0.02	73.8
Study design					
Parallel randomized controlled	5	2.10 (1.76–2.49)	1.93	0.75	0
Crossover randomized controlled	3	1.38 (0.61–3.11)	7.64	0.02	73.8
Study population					
With cancer	0	NA	NA	NA	NA
Without cancer	8	1.88 (1.48–2.39)	13.61	0.06	48.6
Oral Δ-9-tetrahydrocannabinol v. control	13	2.18 (1.59–2.99)	128.34	< 0.001	90.7
Duration of exposure					
> 2 wk	5	1.46 (1.04–2.04)	15.02	0.005	73.4
≤ 2 wk	8	2.91 (1.88–4.50)	59.20	< 0.001	88.2
Study design					
Parallel randomized controlled	5	1.53 (1.10–2.17)	21.05	< 0.001	81
Crossover randomized controlled	8	2.82 (1.94–4.11)	36.19	< 0.001	80.7
Study population					
With cancer	6	2.93 (1.96–4.39)	32.28	< 0.001	84.5
Without cancer	7	1.60 (1.04–2.47)	48.62	< 0.001	87.7
Oral Δ-9-tetrahydrocannabinol-cannabidiol v. control	5	1.31 (0.88–1.96)	24.01	< 0.001	83.3
Duration of exposure					
> 2 wk	4	1.54 (1.14–2.08)	7.68	0.05	60.9
≤ 2 wk	1	0.56 (0.37–0.86)	NA	NA	NA
Study design					
Parallel randomized controlled	2	1.35 (1.24–1.46)	1	0.32	0.3
Crossover randomized controlled	3	1.46 (0.51–4.19)	21.94	< 0.001	90.9
Study population					
With cancer	1	1.13 (0.77–1.64)	NA	NA	NA
Without cancer	4	1.39 (0.80–2.42)	23.12	< 0.001	87.0

Note: NA = not applicable.